Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2017 and annual treatment report for 2012

Abstract

Aim To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2017 and the Annual Treatment Report for 2012, on the outcomes of patients who started treatment in 2012. Methods The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2017 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial and ovarian cancer in 2012 was analyzed by using the Kaplan‐Meier, log‐rank and Wilcoxon tests. Results Treatment was initiated in 2017 for 7710 patients with cervical cancer; 11 120 with endometrial cancer; 7029 with ovarian, tubal and peritoneal cancer; 2164 with ovarian borderline tumors; and with the others (213 vulvar cancer, 139 vaginal cancer, 366 uterine sarcoma, 41 uterine adenosarcoma and 131 trophoblastic diseases). This clinicopathological information was summarized as the patient annual report. The 5‐year survival rates of the patients with cervical cancer were 92.9, 75.5, 58.2 and 26.7% for stages I, II, III and IV, respectively. The 5‐year survival rates for the patients with endometrial cancer were 93.6, 85.6, 72.6 and 27.3% for stages I, II, III and IV, respectively. The 5‐year survival rates for the patients with ovarian cancer (surface epithelial‐stromal tumors) were 92.5, 83.5, 49.5 and 30.8% for stages I, II, III and IV, respectively. Conclusion The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.

Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2018 and Annual Treatment Report for 2013

“…The 5‐year survival rates for cervical, endometrial, and ovarian cancers (all stages) were 71.5%, 78.1%, and 59.4%, respectively. Compared to the 2012 treatment outcomes (cervical cancer: 69.7%, endometrial cancer: 77.8%, and ovarian cancer: 58.0%), 3 there was no notable change in the prognosis for gynecologic cancers in Japan. The American Cancer Society reported the 5‐year survival rate (all SEER stages combined) of 66%, 81%, and 49% for cervical, endometrial, and ovarian cancers, respectively, based on patients diagnosed with those cancers between 2010 and 2016 6 .…”

“…This study investigated the 2018 gynecological malignancy trends in Japan and analyzed the prognosis of gynecological malignancies for treatment was initiated in 2013, as the tumor registries project of the JSOG. According to a comparison of the numbers of patients with gynecological malignancies in 2017 and 2018, there was no significant difference in the number of registered patients for all gynecological malignancy, namely, cervical cancer (2017: 7710, 2018: 7304 patients), endometrial cancer (2017: 11120, 2018: 11230 patients), and ovarian cancer (2017: 7029, 2018: 7031 patients) 3 . There was no change in the respective percentages of registered patients with Stages I–IV cervical, endometrial, ovarian, tubal, and peritoneal cancers in 2018, compared to those in the 2017 Annual Patient Report 3 …”

Evaluation of Clinical Significance of Lymphovascular Space Invasion in Stage IA Endometrial Cancer

“…Furthermore, Beavis et al [17] reported that adjuvant therapy improved progression-free survival compared with observation alone in stage I or II endometrioid endometrial cancer with LVSI. However, there are few reports analyzing the prognostic significance of LVSI in stage IA endometrial cancer, which has a good prognosis, with the 5-year survival rate of 95.1% [15, 18], and thus, we have not administered adjuvant treatment to patients with stage IA low-grade endometrial cancer even with LVSI at our institute. To evaluate the clinical significance of LVSI in stage IA endometrial cancer, we investigated patients with stage IA endometrial cancer in this study.…”

Impact of COVID-19 on gynecologic cancer treatment in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO)

“…The number of patients treated was categorized by stage and compared with the distribution of past data in Japan. Past data as control was extracted from the annual reports of the Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology (JSOG) [ 7 8 9 ]. There was no increase in the rate of advanced stages in the three major cancer types.…”